The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma

被引：0
作者：
Jintao Zhuang
Xiangan Tu
Kaiyuan Cao
Shengjie Guo
Xiaopeng Mao
Jincheng Pan
Bin Huang
Xu Chen
Yong Gao
Shaopeng Qiu
机构：
[1] Sun Yat-sen University,Department of Urology, The First Affiliated Hospital
[2] Sun Yat-sen University,Research Center for Clinical Laboratory Standard, Zhongshan Medical School
[3] Sun Yat-sen University Cancer Center,Department of Urology
来源：
Journal of Experimental & Clinical Cancer Research | / 33卷
关键词：
Renal cell carcinoma; ETK; Small interfering RNA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Structure of Escherichia coli tyrosine kinase Etk reveals a novel activation mechanism
    Lee, Daniel C.
    Zheng, Jimin
    She, Yi-Min
    Jia, Zongchao
    EMBO JOURNAL, 2008, 27 (12) : 1758 - 1766
  • [42] LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma
    Naito, Sei
    Makhov, Peter
    Astsaturov, Igor
    Golovine, Konstantin
    Tulin, Alexei
    Kutikov, Alexander
    Uzzo, Robert G.
    Kolenko, Vladimir M.
    BRITISH JOURNAL OF CANCER, 2017, 116 (09) : 1203 - 1207
  • [43] Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations
    Wang, Kun
    Duan, Pengqiang
    Chen, Xusheng
    Yang, Qing
    Feng, Guowei
    Diao, Lei
    Zhang, Zhenting
    Yao, Xin
    CANCER MEDICINE, 2023, 12 (13): : 14149 - 14156
  • [44] Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases
    B Beuselinck
    P Wolter
    A Karadimou
    R Elaidi
    H Dumez
    A Rogiers
    T Van Cann
    L Willems
    J-J Body
    J Berkers
    H Van Poppel
    E Lerut
    P Debruyne
    R Paridaens
    P Schöffski
    British Journal of Cancer, 2012, 107 : 1665 - 1671
  • [45] Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer
    Guo, Linlang
    Zhou, Yuanyuan
    Sun, Yanqin
    Zhang, Fan
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (03) : 636 - 641
  • [46] Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) reply
    Kourie, Hampig R.
    Bakouny, Ziad
    Haddad, Fady G. H.
    Eid, Roland
    Kattan, Joseph
    FUTURE ONCOLOGY, 2018, 14 (22) : 2225 - 2227
  • [47] LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma
    Sei Naito
    Peter Makhov
    Igor Astsaturov
    Konstantin Golovine
    Alexei Tulin
    Alexander Kutikov
    Robert G Uzzo
    Vladimir M Kolenko
    British Journal of Cancer, 2017, 116 : 1203 - 1207
  • [48] Adjuvant therapy in renal cell carcinoma: Tyrosine kinase inhibitor versus immune checkpoint inhibitor
    Zhou, Qingbo
    Liu, Jianjiang
    Xie, Shaoqin
    MEDICINE, 2024, 103 (22) : E38329
  • [49] Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling
    Holopainen, Tanja
    Rasanen, Markus
    Anisimov, Andrey
    Tuomainen, Tomi
    Zheng, Wei
    Tvorogov, Denis
    Hulmi, Juha J.
    Andersson, Leif C.
    Cenni, Bruno
    Tavi, Pasi
    Mervaala, Eero
    Kivela, Riikka
    Alitalo, Kari
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (42) : 13063 - 13068
  • [50] MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma
    Kovacova, Julia
    Poprach, Alexandr
    Buchler, Tomas
    Cho, William C.
    Slaby, Ondrej
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2018, 56 (09) : 1426 - 1431
12345